The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study

DM Green, VG Nolan, PJ Goodman… - Pediatric blood & …, 2014 - Wiley Online Library
Background Estimation of the risk of adverse long‐term outcomes such as second malignant
neoplasms and infertility often requires reproducible quantification of exposures. The …
被引用次数：442 相关文章

The Cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer Survivor Study

DM Green, VG Nolan… - Pediatric Blood …, 2014 - mdanderson.elsevierpure.com
Background. Estimation of the risk of adverse long-term outcomes such as second malignant
neoplasms and infertility often requires reproducible quantification of exposures. The …

The Cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer Survivor Study

DM Green, VG Nolan… - Pediatric Blood …, 2014 - digitalcommons.memphis.edu
Background. Estimation of the risk of adverse long-term outcomes such as second malignant
neoplasms and infertility often requires reproducible quantification of exposures. The …

The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

DM Green, VG Nolan, PJ Goodman… - Pediatric Blood & …, 2013 - europepmc.org
Background Estimation of the risk of adverse long-term outcomes such as second malignant
neoplasms and infertility often requires reproducible quantification of exposures. The …
[HTML] nih.gov

[HTML][HTML] The Cyclophosphamide Equivalent Dose as an Approach for Quantifying Alkylating Agent Exposure. A Report from the Childhood Cancer Survivor Study

DM Green, VG Nolan, PJ Goodman… - Pediatric blood & …, 2014 - ncbi.nlm.nih.gov
BACKGROUND Estimation of the risk of adverse long-term outcomes such as second
malignant neoplasms and infertility often requires reproducible quantification of exposures …

[引用][C] The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study

DM Green, VG Nolan, PJ Goodman, JA Whitton… - Pediatric Blood & …, 2013 - cir.nii.ac.jp
The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent
exposure: A report from the childhood cancer survivor study | CiNii Research CiNii 国立情報学 …

The Cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer Survivor Study

DM Green, VG Nolan, PJ Goodman… - Pediatric Blood and …, 2014 - experts.umn.edu
Background. Estimation of the risk of adverse long-term outcomes such as second malignant
neoplasms and infertility often requires reproducible quantification of exposures. The …

The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study

DM Green, VG Nolan, PJ Goodman, JA Whitton… - Pediatric Blood & …, 2013 - infona.pl
Background Estimation of the risk of adverse long‐term outcomes such as second malignant
neoplasms and infertility often requires reproducible quantification of exposures. The …

The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study

DM Green, VG Nolan, PJ Goodman… - Pediatric blood & …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Estimation of the risk of adverse long-term outcomes such as second malignant
neoplasms and infertility often requires reproducible quantification of exposures. The …

The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

DM Green, VG Nolan, PJ Goodman… - Pediatric Blood & …, 2013 - europepmc.org
Background Estimation of the risk of adverse long-term outcomes such as second malignant
neoplasms and infertility often requires reproducible quantification of exposures. The …